Adoptive immunotherapy for B16 melanoma slows tumor growth and improves survival in lymphoreplete hosts versus lymphopenic Rag1^−/− hosts. (A) Tumor growth curves (left) and survival curves (right) of treated groups as shown. B16 tumor cells were inoculated subcutaneously at day 0 in the graph. Statistically significant differences (*P < .05, **P < .005), compared with pmel-1 cells transferred mice. (B) Bioluminescence imaging of luciferase-expressing B16 tumors in Thy-B, TXY, and Rag1^−/− mice imaged on day 20 after tumor cells inoculation. Tumor cells injection area (right flank area) were shaved to minimize the amount of light absorbed by black fur. Crosses pointing to necrotic tumors indicate dead mice resulting from tumor progression.